2016 TOP STORIES: Lilly Alzheimer’s drug fails in high-stakes trial
t was the most closely watched experimental drug from Eli Lilly and Co. in years, a potential game-changer for treating the ravages of Alzheimer’s disease.
Health Care & Insurance
Articles
Anthem-Cigna deal cast by U.S. as risk to patients, providers
Anthem Inc. and the U.S. Justice Department extended their clash over whether the insurer’s planned takeover of rival Cigna Corp. will raise costs.
Defendant in American Senior Communities probe agrees to plead guilty
The move by Mainscape founder Dave Mazanowski, disclosed in a federal court filing, is potentially problematic for the four other executives charged this fall.
Lilly shares jump after it offers better-than-expected forecast
Eli Lilly and Co. shares rose sharply Thursday morning after the company presented a better-than-expected 2017 forecast nearly a month after it had announced the failure of a key Alzheimer’s treatment in testing.
Lilly trims profit guidance but says growth strategy on track
The company’s announcement reassured investors in the wake of last month’s news that the Alzheimer’s drug solanezumab had failed to demonstrate effectiveness during a large-scale clinical trial.
My body is the battleground between cancer and chemo
The point of chemo is to cure me. But these are not gentle chemicals. They sweep through my body like a tornado, with side effects that range from annoying to horrendous. But I have no choice.
Lilly to sell insulin at 40 percent discount to cash-paying patients
Eli Lilly and Co. will bypass insurance companies to offer a discount on its best-selling insulin products for patients who lack health coverage or have high deductibles that require them to pay the full cost of some medications.
Anthem-Cigna merger goes to judge for ruling that could end deal
U.S. District Judge Amy Berman Jackson in Washington, D.C., will issue a decision on whether the combination of the companies risks higher costs for large employers around the country and should be blocked.
Tech entrepreneur Don Brown donating $30M to IU School of Medicine
The gift is the largest to the IU School of Medicine by an alumnus. The medical school will use the money to establish the Brown Center for Immunotherapy to fight some of the world’s toughest diseases.
Light ’em if you got ’em—plenty of Hoosiers on Medicaid doing just that
A new report by the Centers for Disease Control and Prevention is pushing states with high Medicaid smoking rates to do more to encourage enrollees to quit and live longer.
Lilly partners with AstraZeneca on another Alzheimer’s treatment
The Indianapolis-based company, which last month struck out in a late-stage clinical trial for a potential Alzheimer’s drug called solanezumab, announced Friday a collaboration with AstraZeneca to develop another possible treatment for the mind-robbing disease.
State official barred from taking job with senior-living company
An Indiana state official in charge of regulatory oversight of nursing homes and residential care facilities has been barred from taking a job at a private company that runs senior living communities over ethics concerns.
Pharma stocks slide after Trump’s vow to control drug costs
President-elect Donald Trump promised to drive down the cost of medicines, defying investors who saw a boon in his election last month and injecting himself again into a contentious economic debate.
Lilly threatens Sanofi’s dominance in insulin with knockoff drug
In a few days, a new type of knockoff medicine will upend a $10 billion diabetes-drug market and exacerbate a brutal price war between some of its biggest players.
Health insurers willing to give up key Obamacare provision
U.S. health insurers signaled Tuesday that they’re willing to give up a cornerstone provision of Obamacare that requires all Americans to have insurance.
After rough November, some good news for Lilly
The FDA says the Indianapolis-based drugmaker and its partner can make an important label claim on its new diabetes drug—a move analysts say could give sales a big boost.
Pharmaceutical firm plans $10.4M in new equipment, 60 jobs
The company has requested a tax break from Indianapolis officials on the project that would save it about $484,000 over eight years.
Lilly competitor to cap price increases as drug costs face more scrutiny
With drug companies under fire, the world’s largest insulin maker plans to limit price increases and introducing a model that ties the cost of medicines to the results they deliver.
Lilly to lay off hundreds after failure of Alzheimer’s drug
Eli Lilly and Co. plans to lay off hundreds of U.S. sales representatives in coming months, following the disappointing failure of an experimental drug for Alzheimer’s disease announced last week.
At Eli Lilly, tears, heartbreak and renewed determination
Eli Lilly and Co. employees knew the Alzheimer's treatment solanezumab was not a sure bet. But that didn’t make the pain any less acute after the company announced the drug had failed to demonstrate effectiveness during a 2,100-patient Phase 3 clinical trial.